HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

David Wild

Reporter

Toronto, Canada
David’s reporting since 2001 has focused on the clinical aspects of medicine, particularly in the American health system. He’s covered everything from novel drugs for inflammatory bowel disease (think back to the advent of biologics!) to protocols for fine-tuning use of anticoagulants post-operatively, and from the fallout of medication compounding disasters to regulatory concerns about the 340B drug pricing program. He has covered dozens of medical conferences and profiled numerous clinicians and institutions. David is a native of Israel and lives in Toronto, Canada. His hobbies include playing music, gardening, camping and spending time with his wife, son and mini-Bernedoodle, Moishe.

Latest From David Wild

Advice From Investors On Early-Stage Financing

Startup financing may be hard to come by, but now is not the time to ask for less cash. 

Growth Financing

Bayer’s BD And Licensing Strategy Key To Moving Through Difficult Period

As Bayer moves through a challenging period, business development, licensing and impact investment may help buttress the company’s resilience

C-Suite Speaks Business Strategies

What Big Pharmas Are Looking For In Partners

With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.

Market Intelligence Innovation

Almirall Goes All In On Generative AI

Dermatology-focused Almirall S.A. is partnering with Microsoft for generative artificial intelligence capabilities. It is the second generative AI-based collaboration announced by Almirall in several months. 

Innovation Market Intelligence

Former Meta Exec: ‘Culture Is The Greatest Challenge To Benefiting From GenAI'

To Jerome Pesenti, the biggest hurdle to integrating generative artificial intelligence into the biopharma industry is accepting that data often knows better than humans.

Innovation Artificial Intelligence

Unraveling #JPM24: Insights From Citeline Reporters And Analysts

As it often does, this year's J.P. Morgan Healthcare Conference could set the tone for the rest of the year in biopharma. In Vivo revisits the key questions coming out of the 2024 event. 

Market Intelligence Deals
See All
UsernamePublicRestriction

Register